Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Barry Paul, MDMS, Myra Robinson, MSPH, Kristen Cassetta, Daniel Slaughter, Jordan Robinson, Ami P Ndiaye, NP, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA, Shebli Atrash, MD

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-141637

Published: 2020

Journal Articles

Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice

Shebli Atrash, MD, Evelyn M. Flahavan, Tao Xu, Esprit Ma, Sudeep Karve, Wan-Jen Hong, MD, Gilbert Jirau-Lucca, Michael Nixon, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 40–43.

https://doi.org/10.1182/blood-2020-134703

Published: 2020

Journal Articles

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Barry Paul, MDMS, James Symanowski, PhD, Paul Osipoff, Sarah Norek, BSN, RN, Ami P Ndiaye, NP, Jordan Robinson, Shebli Atrash, MD, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-141623

Published: 2020

Journal Articles

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Shebli Atrash, MD, Myra Robinson, MSPH, Barry Paul, MDMS, Sarah Norek, BSN, RN, David M. Foureau, PhD, Carrie Ann Syfert, BSN, RN, Ami P Ndiaye, NP, James T Symanowski, PhD, Jordan Robinson, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141562

Published: 2020

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Three Cases of Patients with Complement Regulatory Factor Genetic Mutations and Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Shebli Atrash, MD, David Kent McKelvey, MD, Appalanaidu Sasapu, MD MS, Muthu Veeraputhiran, MD MPH, Soumya Pandey, MD, Michele H. Cottler-Fox, MD, Pooja Motwani, MD

Blood (2016) 128 (22): 1362.

https://doi.org/10.1182/blood.V128.22.1362.1362

Published: 2016

Journal Articles

Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis

Belal Firwana, MD, Mohamad Bassam Sonbol, MD, Shebli Atrash, MD, Rahul Ravilla, MD, Mihir Raval, MD MPH, Lin Hao, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Muthu Veeraputhiran, MD MPH, Issam Makhoul, MD, Appalanaidu Sasapu, MD MS

Blood (2016) 128 (22): 5594.

https://doi.org/10.1182/blood.V128.22.5594.5594

Published: 2016

Journal Articles

Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States

Nishi Shah, Appalanaidu Sasapu, MD MS, Shebli Atrash, MD, Joshi P Krishna, MD, Laura F Hutchins, MD, Peter Dean Emanuel, MD, Yogesh Jethava, MD

Blood (2016) 128 (22): 4782.

https://doi.org/10.1182/blood.V128.22.4782.4782

Published: 2016

Journal Articles

Characteristics and Prognosis Of IgM Multiple Myeloma

Shebli Atrash, MD, Qing Zhang, PhD, Xenofon Papanikolaou, MD, Christoph Heuck, MD, Aziz Bakhous, M.D., Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1881.

https://doi.org/10.1182/blood.V122.21.1881.1881

Published: 2013

Journal Articles

Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival

Xenofon Papanikolaou, MD, Qing Zhang, PhD, Christoph Heuck, MD, Sarah Waheed, MD, Shebli Atrash, MD, Zeba N Singh, MD, Daisy V. Alapat, MD, Frits van Rhee, MD, PhD, Shweta S. Chavan, PhD, Joshua Epstein, DSc, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1911.

https://doi.org/10.1182/blood.V122.21.1911.1911

Published: 2013

Journal Articles

Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL

Christoph Heuck, MD, Pingping Qu, PhD, Emily Hansen, MS, Qing Zhang, PhD, Adam Rosenthal, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Shebli Atrash, MD, Purvi Patel, Antje Hoering, PhD, Joshua Epstein, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1913.

https://doi.org/10.1182/blood.V122.21.1913.1913

Published: 2013

Journal Articles

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Bart Barlogie, MD, PhD, Alan Mitchell, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Monica Grazziutti, MD, Alejandro Restrepo, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Senu Apewokin, MD, Shebli Atrash, MD, Aziz Bakhous, M.D., Sajjad Haider, MD, Surachit Kumar, MD, Jameel Muzaffar, MD, Zainab Shahid, MD, John Crowley, PhD

Blood (2012) 120 (21): 1850.

https://doi.org/10.1182/blood.V120.21.1850.1850

Published: 2012

Journal Articles

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Al-Ola Abdallah, MD, Shebli Atrash, MD, Jameel Muzaffar, MD, Nisar Ahmad, MD, Sajjad Haider, MD, Monica Grazziutti, MD, Senu Apewokin, MD, Zainab Shahid, MD, Alejandro Restrepo, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 2925.

https://doi.org/10.1182/blood.V120.21.2925.2925

Published: 2012

Journal Articles

Conversion of Non-Secretory to Hyper-Secretory Myeloma: The Antithesis of the Common Pathway of Dedifferentiation with Myeloma Progression: A Case Study

Shebli Atrash, MD, Al-Ola Abdallah, MD, Joshua Epstein, DSc, Christoph Heuck, MD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 5052.

https://doi.org/10.1182/blood.V120.21.5052.5052

Published: 2012

Journal Articles

Fatal Thrombotic Microangiopathy Developing within 24 Hours of Carfilzomib in a Patient with Relapsed Multiple Myeloma (MM)

Shebli Atrash, MD, Amy Joiner, K, MD, Bart Barlogie, MD, PHD, Stephen Medlin, DO, FACP

Blood (2012) 120 (21): 5037.

https://doi.org/10.1182/blood.V120.21.5037.5037

Published: 2012

Journal Articles

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Saad Z Usmani, MD, FACP, Emily Hansen, MS, Doug Steward, Sarah Waheed, MD, Susan B. Panozzo, Nathan M Petty, Shebli Atrash, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Antje Hoering, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 4083.

https://doi.org/10.1182/blood.V120.21.4083.4083

Published: 2012

NARROW

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Three Cases of Patients with Complement Regulatory Factor Genetic Mutations and Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis

Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States

Characteristics and Prognosis Of IgM Multiple Myeloma

Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival

Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Conversion of Non-Secretory to Hyper-Secretory Myeloma: The Antithesis of the Common Pathway of Dedifferentiation with Myeloma Progression: A Case Study

Fatal Thrombotic Microangiopathy Developing within 24 Hours of Carfilzomib in a Patient with Relapsed Multiple Myeloma (MM)

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only